Opteev Unveils Novel Multiplex Biochip for Accurate Detection of Respiratory Infections

Opteev Technologies has introduced a revolutionary polymer-based biochip designed to transform respiratory infection diagnostics. 

This innovative biochip has the capability to simultaneously test for a variety of pathogens responsible for respiratory infections, such as SARS-CoV-2, RSV, and Influenza, providing precise identification of the specific virus or bacteria in less than 60 seconds.

This breakthrough technology holds the promise of a rapid, portable, and highly accurate syndromic diagnostic tool, putting immediate results directly into the hands of healthcare providers.

A key advantage of multiplex biochip lies in its affordability and speed. Traditional respiratory panels often come with high costs and lengthy processing times, sometimes taking days to produce results. 

The multiplex biochip enables cost-effective syndromic testing right at the point of care. It enables simultaneous detection and specific identification of multiple pathogens within moments.

The minute-scale biochip has the remarkable ability to instantly detect entire viruses in real-time, working effectively with both processed and unprocessed samples like saliva or nasal swabs.

Its analytical performance evaluation has demonstrated an outstanding accuracy rate of 99.49% and an impressive limit of detection. This precision is achieved by utilizing virus-binding peptides that are meticulously selected for specific targets, ensuring reliable identification of the desired viruses in complex samples. 

Artificial intelligence is employed to optimize the frequency range, skillfully minimizing the impact of interfering noise signals, thus enhancing the biochip's ability to accurately detect viruses.

The development of this multiplex biochip marks a pivotal turning point in point-of-care diagnostics.